CLINICAL TRIAL: THE EFFECT OF RISEDRONATE ON BONE TURNOVER AND BONE MASS IN OLDE

临床试验：利塞膦酸盐对老年骨转换和骨量的影响

• 批准号: 7719094
• 负责人: PAMELA TAXEL
• 金额: $ 0.74万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719094
• 关键词: Cancer Etiology; Carcinoma; Cessation of life; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Disease; Fracture; Funding; Grant; Hip Fractures; Hormonal; Incidence; Institution; Luteinizing Hormone-releasing Hormone Agonist; Population; Prostate; Prostate carcinoma; Public Health; Quality of life; Research; Research Personnel; Resources; Risedronate; Risk; Source; Survivors; Therapeutic Intervention; United States National Institutes of Health; bone; bone loss; bone turnover; cancer diagnosis; high risk men; men; mortality; older men; osteoporosis with pathological fracture

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This proposal will examine a therapeutic intervention with risedronate in a population of men at high risk for bone loss. Carcinoma of the prostate gland is the most commonly diagnosed cancer in U.S. men, and is the second leading cause of cancer death. Over the last decade, more and more men are being treated with hormonal suppression therapy for locally advanced disease. Recent studies have shown that such hormonal suppression with Luteinizing Hormone Releasing Hormone (LHRH) agonists leads to rapid bone loss and increased risk of osteoporotic fractures (1). The increased incidence of hip fractures and other fragility fractures in older men is a major public health issue. Hip fractures are costly, increase mortality and significantly compromise the independence and quality of life of the survivors. The potential for compounding this problem in men treated with hormonal suppression for locally advanced prostate carcinoma is the rationale for this study.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该提案将研究利塞膦酸盐对骨质流失高风险男性群体的治疗干预。前列腺癌是美国男性中最常诊断出的癌症，也是癌症死亡的第二大原因。在过去的十年中，越来越多的男性正在接受激素抑制疗法来治疗局部晚期疾病。最近的研究表明，黄体生成素释放激素 (LHRH) 激动剂的这种激素抑制会导致骨质快速流失并增加骨质疏松性骨折的风险 (1)。老年男性髋部骨折和其他脆性骨折的发生率增加是一个重大的公共卫生问题。髋部骨折代价高昂，会增加死亡率，并严重损害幸存者的独立性和生活质量。这项研究的理由是，在接受激素抑制治疗的局部晚期前列腺癌的男性中，这个问题可能会变得更加复杂。